David Garfield

Summary

Country: USA

Publications

  1. doi request reprint Bronchioloalveolar carcinoma: the case for two diseases
    David H Garfield
    Department of Medicine, University of Colorado Health Sciences Center, Aurora, Colorado, USA
    Clin Lung Cancer 9:24-9. 2008
  2. doi request reprint Documentation of thyroid function in clinical studies with sunitinib: why does it matter?
    David H Garfield
    J Clin Oncol 26:5131-2; author reply 5132-3. 2008
  3. ncbi request reprint The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases
    David H Garfield
    Department of Medicine, University of Colorado Health Sciences Center, Aurora, Colorado 80010, USA
    J Thorac Oncol 1:344-59. 2006
  4. ncbi request reprint Increasing osteoblastic lesions as a manifestation of a major response to gefitinib
    David Garfield
    University of Colorado Health Sciences Center, Boulder, Colorado, USA
    J Thorac Oncol 1:859-60. 2006
  5. ncbi request reprint Unanswered questions regarding the management of sunitinib-induced hypothyroidism
    David Garfield
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80209, USA
    Nat Clin Pract Oncol 4:674. 2007
  6. pmc Thyroid dysfunction in patients treated with sunitinib or sorafenib
    Julia Clemons
    Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Denver, Aurora, USA
    Clin Genitourin Cancer 10:225-31. 2012
  7. ncbi request reprint Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma
    David H Garfield
    Department of Medicine, University of Colorado Health Sciences Center, Aurora, CA, USA
    J Clin Oncol 23:7738-40. 2005
  8. ncbi request reprint Possible mechanism(s) of action of bortezomib in a patient with bronchioloalveolar carcinoma
    David H Garfield
    Lung Cancer 57:249-50. 2007
  9. ncbi request reprint Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
    David H Garfield
    J Natl Cancer Inst 99:975-6; author reply 976-7. 2007
  10. ncbi request reprint Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma
    Mark G Kris
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Thorac Oncol 1:S32-6. 2006

Detail Information

Publications14

  1. doi request reprint Bronchioloalveolar carcinoma: the case for two diseases
    David H Garfield
    Department of Medicine, University of Colorado Health Sciences Center, Aurora, Colorado, USA
    Clin Lung Cancer 9:24-9. 2008
    ....
  2. doi request reprint Documentation of thyroid function in clinical studies with sunitinib: why does it matter?
    David H Garfield
    J Clin Oncol 26:5131-2; author reply 5132-3. 2008
  3. ncbi request reprint The bronchioloalveolar carcinoma and peripheral adenocarcinoma spectrum of diseases
    David H Garfield
    Department of Medicine, University of Colorado Health Sciences Center, Aurora, Colorado 80010, USA
    J Thorac Oncol 1:344-59. 2006
    ..Because of frequent lung-only recurrences, lung transplantation, although performed rarely, may hold promise...
  4. ncbi request reprint Increasing osteoblastic lesions as a manifestation of a major response to gefitinib
    David Garfield
    University of Colorado Health Sciences Center, Boulder, Colorado, USA
    J Thorac Oncol 1:859-60. 2006
  5. ncbi request reprint Unanswered questions regarding the management of sunitinib-induced hypothyroidism
    David Garfield
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80209, USA
    Nat Clin Pract Oncol 4:674. 2007
  6. pmc Thyroid dysfunction in patients treated with sunitinib or sorafenib
    Julia Clemons
    Division of Medical Oncology, Department of Medicine, School of Medicine, University of Colorado Denver, Aurora, USA
    Clin Genitourin Cancer 10:225-31. 2012
    ..The goal of this study was to better characterize the development of hypothyroidism in patients and to examine its relationship to progression-free survival...
  7. ncbi request reprint Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma
    David H Garfield
    Department of Medicine, University of Colorado Health Sciences Center, Aurora, CA, USA
    J Clin Oncol 23:7738-40. 2005
  8. ncbi request reprint Possible mechanism(s) of action of bortezomib in a patient with bronchioloalveolar carcinoma
    David H Garfield
    Lung Cancer 57:249-50. 2007
  9. ncbi request reprint Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
    David H Garfield
    J Natl Cancer Inst 99:975-6; author reply 976-7. 2007
  10. ncbi request reprint Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma
    Mark G Kris
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Thorac Oncol 1:S32-6. 2006
    ..Bronchioloalveolar carcinoma (BAC) is a subtype of adenocarcinoma of the lung with unique pathological, clinical, and molecular characteristics...
  11. ncbi request reprint Significance of the papillary subtype in relation to durable response to gefitinib in advanced non-small cell lung cancer
    David H Garfield
    Lung Cancer 54:259. 2006
  12. doi request reprint A comparison of survival and disease-specific survival in surgically resected, lymph node-positive bronchioloalveolar carcinoma versus nonsmall cell lung cancer: implications for adjuvant therapy
    David H Garfield
    Cancer 113:1107-8; author reply 1108-9. 2008
  13. ncbi request reprint Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer
    Marcus A Neubauer
    US Oncology, Inc, 12941 North Freeway, Suite 700, Houston, TX 77060, USA
    Lung Cancer 47:121-7. 2005
    ..The primary endpoint was objective response rate. Other endpoints were 1-year survival, median survival, median duration of response, median disease-free progression, safety, and quality of life...
  14. ncbi request reprint Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status
    Ramaswamy Govindan
    Washington University School of Medicine, St Louis, MO, USA
    Semin Oncol 31:27-31. 2004
    ..It is hoped that their findings will aid in determining the best treatment options for these patients...